Moderna (MRNA) Earnings Call Presentation

Intismeran autogene (mRNA-4157) - mRNA-4157 is designed to target an individual patient's unique tumor mutation [6] - mRNA-4157 is in Phase 3 study for adjuvant melanoma, which is fully enrolled [6] - mRNA-4157 is in two adjuvant Phase 3 studies for NSCLC, for those with and without prior neoadjuvant treatment [6] - mRNA-4157 is in randomized Phase 2 study for adjuvant high-risk muscle invasive bladder cancer and adjuvant renal cell carcinoma, the latter of which is fully enrolled [6] - mRNA-4157 is in randomized Phase 2 study for high-risk non-muscle invasive bladder cancer (HR NMIBC) [6] - mRNA-4157 is in Phase 1 basket study for solid tumors: Melanoma, Gastric, PDAC, NSCLC [6] Off-the-shelf cancer antigen therapies - mRNA-4359 targets immunosuppressive cells and mechanisms [10] - mRNA-4359 is in Phase 2, with additional indications planned [10, 11] - mRNA-4106 is in Phase 1 [10] - mRNA-4359 encodes for PD-L1 and IDO, targeting both immunosuppressive cells and cancer cells, and is applicable to many different cancer types [15] T-cell engagers - The company is developing two approaches with secreted T-cell engaging antibodies to target surface and intracellular proteins [19] In vivo cell therapy - mRNA-4203 (partnered with Immatics) has an IND open [28]